)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Cereno Scientific
Cereno Scientific (CRNO) investor relations material
Cereno Scientific Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary26 Aug, 2026
Executive summary
Transitioned into clinical execution with multiple value-driving milestones, including the activation of the first site for the global Phase IIb EPIMODE trial of CS1 in pulmonary arterial hypertension (PAH).
Completed all dosing and participant visits in the Phase I PK-bridging study for CS014, with topline results expected in Q3 2026.
Advanced preclinical program CS585 in antiphospholipid syndrome (APS), with IND-enabling activities planned for 2026.
Strengthened financial position through a SEK 60 million directed share issue at a premium to the latest closing price.
Financial highlights
Net sales were SEK 0 for the quarter; capitalized work for own account was SEK 52.4 million, up from SEK 6.1 million year-over-year.
Result after financial items was a loss of SEK 30.5 million for Q2 2026, compared to a loss of SEK 26.6 million in Q2 2025.
Earnings per share before dilution was SEK -0.10 (Q2 2025: SEK -0.09); after dilution SEK -0.09 (Q2 2025: SEK -0.08).
Cash and bank balances at quarter-end were SEK 38.98 million, down from SEK 74.98 million a year earlier.
Equity/assets ratio was 43.2% at quarter-end (Q2 2025: 46.4%).
Outlook and guidance
Key H2 2026 priorities: achieve first patient randomization and dosing in EPIMODE, report CS014 PK-bridging study topline results, advance CS585 preclinical studies, and maintain disciplined capital allocation.
Phase IIb trial for CS014 in PH-ILD planned to start in Q3 2027, subject to supportive PK-bridging results and regulatory alignment.
Topline results from EPIMODE anticipated in Q4 2028, dependent on recruitment timelines.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Cereno Scientific
- Advancing first-in-class HDAC inhibitors for rare cardiopulmonary diseases with strong clinical and market momentum.CRNO
Company presentation - CS1 advances to Phase IIb in PAH as Q1 loss reaches SEK -21.9M; cash at SEK 70.9M.CRNOQ1 2026
- Advanced to global Phase IIb for PAH, secured major financing, and sharpened pipeline focus.CRNOQ4 2025
- CS1 advances to global phase IIb for PAH, targeting disease modification and $3B peak sales.CRNOCMD 2026
- Two Phase 2 trials in rare diseases to launch next year, backed by FDA Fast Track and global partners.CRNOGoCo Investor Days
- Positive phase II-A results in PAH, FDA engagement, and funding secured through 2026.CRNOABGSC Investor Days
- CS1 met safety and efficacy signals in PAH, supporting advancement to pivotal trials.CRNOStudy Result
- Rare disease pipeline advances with strong clinical data, new indications, and strategic partnerships.CRNOCMD 2024
- CS1 showed safety and efficacy in PAH, supporting further clinical development and partnering.CRNOStudy Update
Next Cereno Scientific earnings date
Q3 20264 Nov, 2026
Cereno Scientific
Next Cereno Scientific earnings date
Q3 20264 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Cereno Scientific is a biotechnology company developing epigenetic therapies for cardiovascular and rare diseases. The company focuses on compounds that modulate endogenous defense mechanisms, with applications in thrombosis and inflammation. It operates in preclinical and clinical research stages. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the STO.